:: Ongoing
Cancer Grants
::
Recent
Publications From Funded Grants
Cancer Types
Sanctioned
1.
Gene therapy for head/neck cancer
using combination therapy: Immuno-Cytokine
therapy plus pro-drug activation therapy.
2.
Identification
of Susceptibility Alleles for the Development
of Head and Neck Cancer in Indian Population.
3.
Development
of Adenovirus Herpes simplex Thymidine Kinase/
Ganciclovir strategy for Head and Neck squamous
cell carcinoma: Preclinical studies and large-scale
preparation of clinical grade vector.
4.
Phase II/III
randomized placebo controlled clinical trial
of curcumin in respectable stage III and
IV squamous head and neck cancers (oral cancers).
5.
Phase
II trial of curcumin in advanced Head and
Neck cancer treatment.
1.
Isolation, Characterization of Gliomasphere
forming cells from Glioblastoma Multiforme:
Correlation with Prognostic Factors and Treatment
Outcome.
2.
Glioma serum biomarker
discovery through proteomic approaches.
3.
Study of the signaling
cascades involved in the proliferation and
differentiation
of cancer stem cells in Glioblastoma.
1.
Cytokine gene polymorphism in HPV associated
cervical cancer.
2.
Human papilloma viruses and prognosis
of cervical neoplasia.
3.
TLR expression profile
in Langerhans and Dendritic Cells in invasive
cervical cancer, cervical intraepithelial neoplasia
and chronic cervicitis.
4.
Delineation of Prognostic Biomarkers
of progression of cervical cancer.
5.
Regulatory T cells: a
potential marker of progression of cervical
precancer?
6.
Molecular Pathology of
Cervical Carcinogenesis.
7.
Role of Transcription
Factor STAT3 in Human Papillomavirus 16 (HPV16) – Induced
Cervical Carcinogenesis.
8.
Host-virus interactions
at the genetic and epigenetic levels in HPV
related
cervical cancer in Indian women.
9.
To
study the immune response of T cell dominant
synthetic peptides derived from HPV 16, using
different adjuvants in a mouse model of cervical
cancer.
1.
Correlation between the expression of sex steroid
receptor genes and tumor suppressor/inducer
genes in human thyroid cancer tissues.
2.
Identification of biomarkers
for thyroid malignancies in FNACs.
3.
Expression of miR-200
family, miR-205 and cell surface proteins as
markers of metastasis in thyroid tumors using
real-time PCR and immunohistochemical analysis.
1.
Suppression of oral cancer-specific p53 mutants
by SiRNA
2.
Studies on genetic susceptibility
factors in oral cancer and precancer lesions
with reference to metabolic and DNA repair
genes.
3.
Development and characterization
of Autologous NKT Cell based Dendritic Cell
Vaccine for Active Specific Immunotherapy of
Oral Squamous Cell Carcinoma.
4.
Study on the significance
of Micro-RNA expression pattern in oral carcinoma.
5.
Molecular ecology, molecular
genetics and natural history of anterior tongue
cancer in young adults without (or insignificant)
tobacco exposure: can a distinct clinical entity
be defined?
6.
A study to evaluate the
role of curcumin in oral premalignant lesions
and gingivo-buccal cancers.
7.
Cytomodulins in oral
cancer therapy.
8.
Loss of heterozygosity
on specific chromosomal arms and influence
of single nucleotide polymorphisms in XRCC1and
XPD genes in oral and esophageal cancers induced
by raw betel-nut in Meghalaya.
9.
Study on the significance
of Micro-RNA expression pattern in oral carcinoma.
Phase-II: Validation of microarray results
and assessment of its prognostic significance.
10.
Identifying surface marker
signature of oral cancer stem cells to develop
a prognosis marker for oral squamous cell carcinoma
using peptide-based CSC detection.
11.
Salivary transcriptome
and proteome for the diagnosis and prognosis
of
oral cancer.
12.
Phase II/III, double
blind, randomized, chemoprevention trial of
curcumin
in oral premalignant lesions.
13.
Clinical and patho-biological
effects of curcumin on oral leukoplakia: A
double blind placebo controlled randomized
trial.
1.
A comprehensive understanding of the
Nasopharyngeal Carcinoma (NPC) in the North-Eastern
Region
of India.
2.
Immuno-genetic profile
of nasopharyngeal cancer in a high-prevalence
region of Northeast India.
1.
Designing of Methylation target
arrays for Breast Cancer
2.
Role of osteopontin, a chemokine
like protein in regulation of vascular endothelial
growth factor dependent tumor growth and angiogenesis
in breast cancer.
3.
Altered Expression of
tumor suppressor SMAR1 in breast cancer causes
deregulation of cyclin D1.
4.
Role of gap junctions
in the bystander effect in breast cancer cells.
5.
Study on gene expression
and Hypermethylation profiles in early onset
breast cancer.
6.
Evaluation of circulating
tumor DNA in serum of breast cancer patients.
7.
Role of STAT3 as downstream
mediator of steroid and epidermal growth factor
pathways in breast cancer.
8.
Analysis of Immunological
parameters in breast tumors in the context
of age at diagnosis.
9.
Neuroendocrine-Immune
interactions in mammary tumorigenesis.
10.
Silencing of MTA1 gene
as a strategy to inhibit tumor angiogenesis
and
metastasis; Role in breast cancer therapy.
11.
Internal Ribosome Entry
Site (IRES) mediated expression of endogenously
produced carboxy-terminal domain of Connexin
43 (CT-Cx43): Status of expression in the breast
cancer.
12.
Embryonic zebrafish as
a model system to study the expression and
role
of breast tumour kinase (brk/ptk6).
13.
Evaluate the mechanism
of resveratrol mediated apoptosis in cigarette
smoke induced breast cancer.
14.
Sequence
dependent molecular action of ZD6474 with
paclitaxel and radiation in progression and
treatment of breast cancer.
1.
Targeting human lung cancer: A preclinical
and mechanistic investigation towards understanding
lung metastasis.
2.
Role of poly N-acetyl
lactosamine substituted ß1,6 branched
N-oligosaccharides in facilitating organ specific
metastasis of melanoma cells to the lungs.
Esophageal Squamous Cell
Carcinoma
1.
Identification of novel esophageal squamous
cell carcinoma (ESCC) genes by using a combination
of array based CGH and gene expression microarrays.
2.
To study frequency and
load of Human Papilloma Virus (HPV) in benign,
pre-malignant (dysplastic) and malignant esophageal
squamous epithelium by immunohistochemistry
and real time PCR.
1.
Functional genomic delineation of convolutions
in Wnt signaling pathway for gastric cancer
diagnostics.
1.
Tumor primordial cells in colorectal
cancer: implications for surgical margins and
minimal
residual disease.
2.
Chemotherapeutic role
of pronyl-lysine against 1,2-dimethylhydrazine
induced colon cancer in male albino Wistar
rats.
3.
Study on the chemopreventive
response of Dolastatin, a mollusc linear peptide
of Indian Ocean origin in experimental colon
cancer.
1
A study of Mutational and Histopathological
risk factors for Gallbladder Cancer in patients
with Gallstones.
1.
Gene mutations in patients with
chronic pancreatitis and their role in pathogenesis
of malignant transformation.
2.
Investigating the
role of P21 activated kinase 1 (Pak1) signaling
in pancreatic adenocarcinoma (PDAC).
1.
Evaluation of the potential of
two monoclonal antibodies for treatment of
androgen-independent
prostatic carcinomas.
2.
Role of small molecule
inhibitor(s) as targeted therapy in pancreatic
and prostate cancers using in vitro and in
vivo models.
1.
Role of nuclear and mitochondrial
genes in the aetiology of uterine leiomyomata
(fibroids).
2.
Evaluation of curcumin
in the management of advanced cancer cervix.
3.
Investigation on the
clearance of human papillomavirus infection
in uterin cervix by BASANT, a polyherbal vaginal
cream and curcumin.
1.
A DNA repair gene-potential marker for
Ovarian cancer.
2.
Combination of P53, EGFR
status and tumor grading in determining the
outcome of early stage epithelial ovarian cancers.
1.
Establishment of molecular cytogenetics
in combination with protein markers for accurate
diagnosis and prognostic prediction of bone
and soft tissue sarcomas.
1
Molecular monitoring
of secondary mutations potentially involved
in disease transformation
of CML to CML-Blast Crisis.
2.
Endothelial progenitor cells
as biomarker of disease activity in multiple
myeloma.
3.
To study the molecular biology
of Multiple myeloma.
4
Immunotherapy of drugs refractory
leukemias and lymphomas expressing hCG or subunits
by a highly specific recombinant chimeric antibody
against ß-hCG linked to curcumin or other
drugs.
5.
Evaluation of Prognostic Value
of FDG-PET after two cycles of Chemotherapy
in Pediatric and Adolescent High Grade Lymphomas.
6.
Assessment of therapeutic response
of radiolabeled anti CD20 antibodies 131Iodine
Rituximab & 90Yttrium Rituximab in diffuse
large B cell non-Hodgkin’s
lymphoma.
7.
Designing of cost effective,
quick and easy visualization method for detection
of CML, AML and ALL leukemia patients using
Molecular Beacons.